Identification of PRDX5 as A Target for The Treatment of Castration-Resistant Prostate Cancer

CRPC drugs work by either reducing dihydrotestosterone biosynthesis, or blocking androgen receptor (AR) signaling. Investigators demonstrated that AR inhibitor treatment gave rise to a drug-tolerant persister state.